If you are basing this on the recent news of the swine flu, the answer is no.
Novavax is just one of over a DOZEN companies that will be “handed” the vaccine by the CDC.
We anticipate that the price of the vaccine will be regulated by the Obama administration and the profits will not be as large as most people expect.
Also, the vaccine is months away from being produced and then it must go through heavy testing phase to make sure it doesn’t make people sick or even kill them.
The recent press about NVAX was a “bump” and some made great money for 48 hours.
Now it is back to common sense. Can they make a profit?
With only a 5000 sq foot facility to produce the vaccine, we don’t see them as a big player.

We do prefer INO, Inovio Biomedical Corp as a better choice.

They may play a more “interim” role with the problem and they just merged with VGX Pharmaceuticals Inc.
This one looks to be a player and we hope it will go over $3 within the next 12 months.